Gilead Sciences

News

Gilead challenges ViiV in resistant HIV, filing twice-yearly...

Gilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs to be administered once every six months.

News

The diagnosis Hepatitis written on a clipboard

Gilead preps filing for hepatitis D therapy Hepcludex in US

Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug's safety and efficacy was sho

News

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

Armed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme for domvanalimab, its anti-TIGIT antibody.

News

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

News

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing

News

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL...

Novartis' Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences' Kite subsidiary is now looming in the rear view mirror – ar

Gilead challenges ViiV in resistant HIV, filing twice-yearly...

Gilead preps filing for hepatitis D therapy Hepcludex in US

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks